38605-72-0

Usage

Synthesis Reference(s)

The Journal of Organic Chemistry, 38, p. 1743, 1973 DOI: 10.1021/jo00949a030

InChI:InChI=1/C13H7ClOS/c14-9-5-3-7-11-12(9)13(15)8-4-1-2-6-10(8)16-11/h1-7H

Upstream product

• 147-93-3 Thiosalicylic acid 
• 108-37-2 1-bromo-3-chlorobenzene 
• 13420-58-1 2-[(3-chlorophenyl)thio]-benzoic acid 

Relevant academic research and scientific papers

Triplet decay-induced negative temperature dependence of the transient photoluminescence decay of thermally activated delayed fluorescence emitter

The photophysical properties of three TX-based D-A isomers (TXO-PhCz1, TXO-PhCz3, and TXO-PhCz4) with a PhCz donor at different substitution positions of phenyl group on a TXO unit were investigated. The substitution position of the PhCz unit significantly impacts the photophysical properties of these isomers. TXO-PhCz1 exhibits a very weak emission in both undoped and doped films, while TXO-PhCz3 and TXO-PhCz4 exhibit a strong emission with the requisite properties for TADF emitters, including a small ΔEST and transient PL decay curves with a prompt and delayed fluorescent component. TXO-PhCz4 exhibits a much stronger orbital coupling than TXO-PhCz3 and then the phosphorescent emission causes the inverse temperature dependence of the transient PL decay, which is contrary to that of TXO-PhCz3 and other TADF emitters. TXO-PhCz4 exhibits a small ΔEST of 23 meV and a short decay time of 14 μs at room temperature, which are much smaller and shorter than those of TXO-PhCz3. Multilayer OLEDs based on TXO-PhCz4 exhibit a very low-efficiency roll-off with a maximum current efficiency of 49.2 cd A-1, a maximum power efficiency of 47.7 lm W-1, and a maximum EQE of 16.3%.

Thioxanthenone antitumor agents

Compounds having anti-tumour activity are disclosed having the formulawherein: (1) n is 2 or 3;R1 and R2 are independently lower-alkyl;Q is a residue chosen from the group consisting ofCH2NHR3, CH2N(R4)SO2R7, CH2NHCHO, CH=N-Ar,C(O)NR5R6, CH2N(R4)C(O)R7, CH2N(C2H5)CHO,CH2N(R4)P(O)(O-lower-alkyl)2, CH2N=CH-N(R9)(R10),CH2N(R4)C(O)CF3 and CH2N(R4)C(O)OR7;R3 is hydrogen or lower-alkyl;R4 is hydrogen, lower-alkyl or Ar;R5 is hydrogen, lower-alkyl or Ar;R6 is hydrogen or lower-alkyl;R7 is lower-alkyl, or Ar;R8 is hydroxy;Ar is phenyl or phenyl substituted with methyl, methoxy, hydroxy, halogen or nitro; andR9 and R10 are independently lower-alkyl; or(2) Q is a residue chosen from the group consisting of CH2N(R4)SO2R7, CH=N-Ar, C(O)NR5R6, CH2N(R4)C(O)R7, CH2N(R4)P(O)(O-lower-alkyl)2, CH2N(R4)C(O)CF3 and CH2N(R4)C(O)OR7; R8 is hydrogen, lower-alkyl, lower-alkoxy, or hydroxy; Ar is phenyl substituted by hydroxy; and n, R1, R2, R4, R5, R6, and R7 are as defined hereinabove in part (1) with the proviso that one or more of R4, R5, or R7 is Ar; or(3) Q is a residue chosen from the group consisting of CH2N=CH-N(R9)(R10) and CH2N(R4)C(O)CF3 ; R8 is hydrogen, lower-alkyl, lower-alkoxy, or hydroxy; and n, R1, R2, R4, R7, Ar, R9 and R10 are as defined hereinabove in part (1), or a pharmaceutically acceptable acid-addition salt or solvate thereof . Compositions containing the thioxanthenones and methods of treating tumors and cancer in mammals with the thioxanthenones are also disclosed.